Treatment of desmoid tumors in Gardner's syndrome

Abstract

Aggressive desmoid tumors present difficult problems among patients with Gardner's syndrome. Recently, attention has been directed toward metabolic or hormonal manipulation of these tumors. A 21-year-old woman with Gardner's syndrome was admitted because of recurrent abdominal wall tumors. She was treated with nonsteroidal anti-inflammatory drugs, tamoxifen, and ascorbate for seven months. During this therapy, CT scan showed a gradual increase in size of the tumors. Subsequent resection of the abdominal tumors and the colon was performed. Although these three types of drugs were administered to prevent postoperative recurrence, an abdominal wall desmoid tumor that invaded the mesentery developed within nine months. The known treatments, that is, chemotherapy, irradiation, and surgical resection are discussed in view of this experience.

Different phenotypes of gastric fundic gland polyposis and cancer in patients with familial adenomatous polyposis depending on Helicobacter pylori infection

“…In Western countries, gastric cancer occurs at a roughly similar rate among FAP and non-FAP patients [12], whereas an increased risk of gastric cancer in Asian FAP patients has been reported [13]. Among Japanese FAP patients, the incidence of gastric cancer has been reported to range from 4.5 to 13.6% [14,15], and the relative mortality risks were 2.7 for male and 4.2 for female patients [12]. The mortality rate due to gastric cancer among FAP patients is 2.8% [16], and the risk is heightened for patients who have undergone prophylactic colectomies [17].…”

Oral Mucositis Severity Assessment by Supplementation of High Dose Ascorbic Acid During Chemo and/or Radiotherapy of Oro-Pharyngeal Cancers – A Pilot Project

“…26 The literature search has revealed total of six studies using oral ascorbate among which three were randomized control trials (RCTs), one each were phase II study, observational study and a case report. [27][28][29][30][31][32] In RCTs, patients with advanced cancers of all types were included and the dosage of oral ascorbate ranged from 1 gm to 10 gm with mean dose of 6.3 gm. [27][28][29][30][31] The outcome from these studies reported as overall survival and overall response and safety in one study.…”

Gastrointestinal Delivery of Anti-inflammatory Nanoparticles

“…In this class of drugs, NSAIDs are widely used as a major treatment for IBD and colon cancer prevention and treatment. Clinical trials tested sulindac (Koornstra et al, 2005;Waddell and Loughry, 1983), indomethacin (Itoh et al, 1988), and acetyl salicylic acid (Paganinihill et al, 1989;Rosenberg et al, 1991a,b). For oral intake or intravenous injection of the classical drug, the bioactive component is distributed throughout the body without any distinctions between healthy and inflamed tissue.…”